MedPath

Psyllium Fiber Versus Placebo in Early Treatment After STARR for Obstructed Defecation: a Double-blind RCT

Phase 4
Completed
Conditions
Constipation
Incontinence
Interventions
Registration Number
NCT02136693
Lead Sponsor
Francesco Gabrielli
Brief Summary

This study aims to assess whether fiber intake, formerly recommended only before or instead of surgery, may play a role in improving postoperative progress and functional outcome after STARR for obstructed defecation, in terms of residual constipation, incontinence and defecation urgency.

Detailed Description

After obtaining written informed consent and collecting baseline scores (T0), each patient was randomly assigned to one of the two groups and began taking sachets containing Psyllium fiber 3.5 g / day for Active group (A) and inert compound for Placebo group (P).

Sachet content was assigned by software randomization, written on a list and sealed in an envelope, which was opened only after the study was completed.

Post-operative instructions for both groups included only analgesic therapy (Ketorolac 10 to 30 mg b.m. if needed). Patients were also asked to stop any former laxative and to continue on a normal diet.

Each patient was re-evaluated at 7 ± 3 (T1), 60 ± 5 (T2) and 180 ± 15 (T3) days after surgery (Table 2).

A fluoroscopic colpocystodefecography (with patient sitting upright) was obtained before surgery and between 60-180 days postoperatively in order to assess comparability of the two groups and exclude negative organic outcomes that could affect functional results.

Medical events were investigated while checking each patient, with special regard to defecation urgency. From the data collected on concomitant medications, we extrapolated those related to laxative intake.

The treatment was considered accomplished in patients who had taken at least 70% of the product during each interval of follow-up.

Statistical analysis was performed using the SPSS - PASW Statistics 18.0.0 (IBM ©, 2009).

For the general and defecographic characteristics, the data are expressed in the form of mean ± standard deviation for continuous variables and absolute frequency (frequency percentages) for categorical variables. The differences between the two groups were calculated by two-tailed t-test or chi-square when appropriate.

Scores for the assessment of clinical data are expressed as mean ± standard deviation and analysis of the differences in the two groups was performed using the two-tailed t-test. The analysis of not normally distributed variables was conducted using a non-parametric test (Wilcoxon-Mann-Whitney).

Analyses related to defecation urgency and use of laxatives were carried out using chi-square test and the data are expressed as absolute frequency (frequency percentage).

For all tests, a value of p \<0.05 was considered significant.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
65
Inclusion Criteria
  • Written informed consent
  • Age over 18
  • Diagnosis of Obstructed Defecation Syndrome according to ODS and CCS Score
  • STARR performed when ODS score >10
  • STARR performed 48-72 hours before
Exclusion Criteria
  • Puborectalis or sphincter dyssynergia, evaluated by defecography and / or anorectal manometry
  • Concomitant diseases (fissure, abscess, fistula, IBD, diverticular disease)
  • Prolapse of other pelvic floor organs
  • Proctological surgery before STARR
  • Pregnancy or breast-feeding
  • Ongoing treatment with oral anticoagulants or steroid therapy
  • Conditions that do not allow patients to understand the nature and the purpose of the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo3.5 g /day of inert compound for 180 days after STARR
Psyllium fiberPsyllium fiber3.5 g /day of pure Psyllium fiber for 180 days after STARR
Primary Outcome Measures
NameTimeMethod
residual constipation180 days after STARR

ODS score and CCS score

Secondary Outcome Measures
NameTimeMethod
change in fecal incontinence from baseline180 days after STARR

Wexner Incontinence score

revertence to laxative use180 days after STARR

frequency percentage of patients that reverted to laxative use after surgery

Post-operative pain180 days after STARR

VAS

post-operative defecation urgency180 days after STARR

defecation urgency incidence

Trial Locations

Locations (1)

Istituti Clinici Zucchi

🇮🇹

Monza, MB, Italy

© Copyright 2025. All Rights Reserved by MedPath